TNF inhibitor impacts, new ACR guidelines lead juvenile arthritis revelations
Click Here to Manage Email Alerts
Patients with juvenile idiopathic arthritis who undergo therapy with TNF inhibitors have an outsized risk for later developing psoriasis, and other revelations, led Healio’s coverage of juvenile arthritis in 2022.
Check out the year’s top-performing stories detailing juvenile idiopathic arthritis from Healio below:
TNF inhibitor use in juvenile idiopathic arthritis triples risk for psoriasis
Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases. Read more.
ACR guidelines: ‘Turn the pyramid upside down’ for biologic DMARDs in JIA
The American College of Rheumatology has released two updated guideline papers for the treatment and management of juvenile idiopathic arthritis, according to a press release. Read more.
Pfizer COVID-19 vaccine offers similar protection in adolescents with, without IRDs
The Pfizer-BioNTech COVID-19 vaccine offers similar protection against the disease in adolescent patients with and without inflammatory or immune rheumatic conditions, according to data published in Rheumatology. Read more.
More than 75% of children with arthritis report pain that interferes with sleep, attention
More than 75% of patients with juvenile idiopathic arthritis experience pain that has interfered with their ability to sleep, pay attention and run or walk short distances, according to an Arthritis Foundation report. Read more.
Adolescents wait longer than younger children to see pediatric rheumatologist for JIA
Adolescents experience longer wait times to see a pediatric rheumatologist for juvenile idiopathic arthritis, compared with younger children, according to research published in the Journal of Rheumatology. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts